$5.42 Billion is the total value of Redmile Group, LLC's 80 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 181.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FATE | Buy | FATE THERAPEUTICS INC | $433,326,000 | +73.9% | 12,629,737 | +12.6% | 8.00% | +14.5% |
| ADCT | New | ADC THERAPEUTICS SA | $258,666,000 | – | 5,525,870 | +100.0% | 4.78% | – |
| BNTX | Buy | BIONTECH SEsponsored ads | $204,836,000 | +1960.7% | 3,069,164 | +1703.3% | 3.78% | +1255.2% |
| PRNB | Buy | PRINCIPIA BIOPHARMA INC | $162,174,000 | +20.8% | 2,712,388 | +20.0% | 2.99% | -20.5% |
| IMMU | New | IMMUNOMEDICS INC | $123,682,000 | – | 3,489,900 | +100.0% | 2.28% | – |
| PLRX | New | PLIANT THERAPEUTICS INC | $110,710,000 | – | 3,410,657 | +100.0% | 2.04% | – |
| ATRA | Buy | ATARA BIOTHERAPEUTICS INC | $99,708,000 | +121.3% | 6,843,370 | +29.3% | 1.84% | +45.8% |
| CI | Buy | CIGNA CORP NEW | $91,217,000 | +71.3% | 486,100 | +61.7% | 1.68% | +12.8% |
| ZNTL | New | ZENTALIS PHARMACEUTICALS INC | $79,771,000 | – | 1,661,205 | +100.0% | 1.47% | – |
| REPL | Buy | REPLIMUNE GROUP INC | $77,139,000 | +159.6% | 3,104,193 | +4.2% | 1.42% | +70.9% |
| RPTX | New | REPARE THERAPEUTICS INC | $74,019,000 | – | 2,386,174 | +100.0% | 1.37% | – |
| GNMK | New | GENMARK DIAGNOSTICS INC | $72,129,000 | – | 4,903,400 | +100.0% | 1.33% | – |
| HRC | New | HILL ROM HLDGS INC | $64,221,000 | – | 585,000 | +100.0% | 1.19% | – |
| SNY | New | SANOFIsponsored adr | $62,562,000 | – | 1,225,500 | +100.0% | 1.16% | – |
| STOK | Buy | STOKE THERAPEUTICS INC | $59,630,000 | +20.2% | 2,502,306 | +15.5% | 1.10% | -20.8% |
| KRYS | Buy | KRYSTAL BIOTECH INC | $58,392,000 | +28.4% | 1,409,745 | +34.0% | 1.08% | -15.5% |
| PPD | Buy | PPD INC | $51,817,000 | +125.4% | 1,933,473 | +49.8% | 0.96% | +48.4% |
| DVAX | New | DYNAVAX TECHNOLOGIES CORP | $44,901,000 | – | 5,062,100 | +100.0% | 0.83% | – |
| AMED | Buy | AMEDISYS INC | $44,903,000 | +37.8% | 226,165 | +27.4% | 0.83% | -9.3% |
| ICUI | New | ICU MED INC | $37,120,000 | – | 201,400 | +100.0% | 0.68% | – |
| BSX | New | BOSTON SCIENTIFIC CORP | $31,506,000 | – | 897,355 | +100.0% | 0.58% | – |
| LMNX | New | LUMINEX CORP DEL | $29,860,000 | – | 917,907 | +100.0% | 0.55% | – |
| CLDX | New | CELLDEX THERAPEUTICS INC NEW | $26,000,000 | – | 2,000,000 | +100.0% | 0.48% | – |
| GH | New | GUARDANT HEALTH INC | $24,146,000 | – | 297,619 | +100.0% | 0.45% | – |
| IMVT | New | IMMUNOVANT INC | $14,610,000 | – | 600,000 | +100.0% | 0.27% | – |
| NVTA | New | INVITAE CORP | $13,058,000 | – | 431,100 | +100.0% | 0.24% | – |
| SLQT | New | SELECTQUOTE INC | $12,586,000 | – | 496,872 | +100.0% | 0.23% | – |
| RPRX | New | ROYALTY PHARMA PLC | $9,710,000 | – | 200,000 | +100.0% | 0.18% | – |
| BMYRT | Buy | BRISTOL-MYERS SQUIBB COright 99/99/9999 | $8,832,000 | -2.7% | 2,467,000 | +3.3% | 0.16% | -36.1% |
| AYLA | New | AYALA PHARMACEUTICALS INC | $6,687,000 | – | 666,666 | +100.0% | 0.12% | – |
| BNR | New | BURNING ROCK BIOTECH LTDsponsored ads | $3,617,000 | – | 133,931 | +100.0% | 0.07% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 43 | Q3 2023 | 10.1% |
| ATARA BIOTHERAPEUTICS INC | 36 | Q3 2023 | 6.4% |
| FATE THERAPEUTICS INC | 34 | Q3 2023 | 17.2% |
| INVITAE CORP | 32 | Q3 2023 | 2.7% |
| REGENXBIO INC | 28 | Q3 2023 | 3.8% |
| CLOVIS ONCOLOGY INC | 27 | Q1 2020 | 6.7% |
| IMMUNOGEN INC | 27 | Q3 2023 | 13.2% |
| CASTLIGHT HEALTH INC SAN FRAN COM STK | 27 | Q1 2021 | 2.5% |
| ARRAY BIOPHARMA INC | 26 | Q2 2019 | 12.6% |
| DECIPHERA PHARMACEUTICALS IN | 25 | Q3 2023 | 7.0% |
View Redmile Group, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | July 27, 2023 | 2,912,228 | 6.6% |
| IGM Biosciences, Inc. | June 28, 2023 | 3,291,092 | 9.9% |
| MedAvail Holdings, Inc. | June 21, 2023 | 124,507,268 | 73.1% |
| Achilles Therapeutics plc | February 14, 2023 | 1,608,089 | 3.9% |
| Kymera Therapeutics, Inc. | February 14, 2023 | 2,673,837 | 4.9% |
| Old Ayala, IncSold out | February 08, 2023 | 0 | 0.0% |
| Zymeworks Inc. | August 08, 2022 | 5,758,241 | 9.9% |
| Science 37 Holdings, Inc. | June 15, 2022 | 19,808,234 | 17.1% |
| Allakos Inc. | February 14, 2022 | 2,077,875 | 3.8% |
| Aprea Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Redmile Group, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-10 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-19 |
| 4 | 2024-03-14 |
| 4 | 2024-03-13 |
| SC 13D/A | 2024-03-13 |
View Redmile Group, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.